Hematin therapy in porphyric attacks
- PMID: 7453089
- DOI: 10.1007/BF01491103
Hematin therapy in porphyric attacks
Abstract
We report our experience with hematin in the treatment of 57 patients in porphyric attacks. The ratio of acute intermittent porphyria: variegate porphyria: hereditary coproporphyria was 43:11:3. More than 90% of the patients showed not only a decline in their porphyrin precursors, but also a favor able clinical response. Hematin was well tolerated and should be considered the treatment of choice in porphyric relapse.
References
MeSH terms
Substances
LinkOut - more resources
Medical